Empagliflozin Protects Cardiac Mitochondrial Fatty Acid Metabolism

Researchers from the Laboratory of Pharmaceutical Pharmacology have shown that empagliflozin treatment preserves mitochondrial fatty acid oxidation in the heart under conditions of chronic lipid overload.

The research was performed within the Horizon 2020 FAT4BRAIN project and published in the journal Cardiovascular Drugs and Therapy (IF=3.367, 2018).

Makrecka-Kuka M., Korzh S., Videja M., Vilks K, Cirule H., Kuka J., Dambrova M., Liepinsh E.   Empagliflozin Protects Cardiac Mitochondrial Fatty Acid Metabolism in a Mouse Model of Diet-Induced Lipid Overload.   Cardiovasc. Drugs. Ther. 2020. doi: 10.1007/s10557-020-06989-9

This entry was posted on .